Vivian Wang


Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

Vivian Wang guides clients on all aspects of antitrust matters, especially through the antitrust merger review processes and in antitrust government investigations across a wide range of industries, including technology, life sciences, financial services, consumer goods and business services. She is also experienced in anti-corruption investigations and compliance counseling.

Prior to joining the firm, Vivian worked at the DC offices of prominent US law firms.


  • Mandarin Chinese
  • English


Bar Admissions

  • New York
  • District of Columbia


  • New York University School of Law, J.D.
  • Georgetown University Law Center, LL.M.
  • Peking University, LL.B.; B.A.

Professional Activities


  • American Bar Association, Antitrust Section
  • Sanofi in its US$1.9 billion acquisition of Kadmon Holdings, Inc.
  • Sanofi in its US$3.2 billion acquisition of Translate Bio
  • Foley Trasimene Acquisition Corp. in its $7.3 billion merger with Alight Solutions LLC
  • Sanofi in its US$1.45 billion acquisition of Kymab, Ltd.
  • Foley Trasimene Acquisition Corp. II in its US$9 billion merger with Paysafe
  • Black Knight in its US$1.8 billion acquisition of Optimal Blue
  • Allergan plc in its US$63 billion sale to AbbVie Inc.
  • A US investment holding company in its unsolicited offer to acquire a real estate data & analytics company
  • Various private equity funds in the acquisitions in the pharmaceuticals, logistics and data & analytics sectors
  • Various Chinese State-Owned-Enterprises in anti-corruption investigations and the design and implementation of compliance programs